ClinicalTrials.gg
RecruitingNCT06092580Updated Sep 2, 2025

Phase 1 Study of AWT020 in Advanced Cancer

A Phase 1 interventional study of AWT020 in Advanced Cancer, sponsored by Anwita Biosciences. Recruiting at 4 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-02.

Sponsored by Anwita Biosciences · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The aims of this clinical trial are (1) to assess the safety of AWT020 at different dose levels; (2) to determine the pharmacokinetics and pharmacodynamics of AWT020 in subjects with locally advanced or metastatic cancer who have failed standard therapy.

Read the detailed description

This study will enroll subjects with locally advanced or metastatic cancer who have failed standard therapy. Subjects enrolled into this study will be assigned a dose level and receive AWT020 via intravenous infusion at a regular interval. The treatment will be continued until disease progression, withdrawal from study or death. The primary objective is to investigate the safety of this agent. The secondary objective is to investigate the pharmacokinetics, pharmacodynamic, potential anti-tumor activity and immunogenicity of this agent.

02

Conditions studied

  • Advanced Cancer

Keywords

  • AWT020
  • anti-PD1
  • Interleukine-2
  • Phase 1
  • First in human
03

In context

Lead sponsor

Anwita Biosciences is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has provided prior to initiation of any study specific activities or procedures.
  • Subject must be ≥ 18 years of age or per local regulation.
  • Subjects must have a histological diagnosis of solid tumors (carcinoma or sarcoma) or malignant lymphoma, either progressive locally advanced not amenable to local therapy or , which is , ineligible (in the opinion of the Investigator) or intolerant to standard therapy. Subjects with hepatocellular carcinoma must be diagnosed with dynamic CT or MRI if no tissue diagnosis is available.
  • Subject must have performance status of 0, or 1 on the performance scale.
  • Subject with adequate organ function.
  • is longer than three months.
  • Subject must be able to receive effective measures.

Exclusion criteria

Exclusion Criteria:

  • Subject is allergic or intolerant to either anti-PD1 or interleukin-2 therapy.
  • Subject has received prior immune-check point inhibitors and was discontinued due to greater than grade 3 toxicities.
  • Subject is receiving other agent or device.
  • Subject has active infection, uncontrolled hypertension, unstable angina, uncontrolled diabetes mellitus, recent myocardial infarction, and congestive heart failure with less than 50%.
  • Subject has prior allogeneic stem cell or bone marrow transplant or organ transplant.
  • Subject has active central nervous system (CNS) or carcinomatous meningitis.
  • Subject with whose viral load is > 400 copies/mL or are \< 350 cells/µL.
  • Subject has baseline interval (QTc) longer than 480 ms by Fridericia formula.
  • Subject is pregnant or breast-feeding.
  • Subject has received within 28 days prior to the first dose of study.
  • Any other conditions that might compromise the safety of the subject or the integrity of the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    AWT020

    Participants receiving intravenous infusion of AWT020

    Biological: AWT020

Interventions

  • BiologicalAWT020

    Participants receiving AWT020 once every two weeks or longer at designated dose levels

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE 5.0

    The overall safety of AWT020 in treated subjects

    Time frame: From the first infusion up to 90 days after last infusion

Secondary outcomes

  1. Cmax of AWT020

    The highest serum concentration of AWT020 after infusion

    Time frame: 30 minutes after the first infusion in cycle 1 and cycle 2

  2. Area under the serum concentration versus time curve (AUC) of AWT020

    The overall exposure of AWT020 after infusion

    Time frame: First infusion to the end of week 2

  3. Half-life of AWT020

    The time for the serum concentration of AWT020 to reduce by half

    Time frame: First infusion to the end of week 2

  4. Immunogenicity of AWT020

    The percentage of treated subjects to develop anti-drug antibody against AWT020

    Time frame: Baseline to Cycle 7 Day 1 (each cycle is 28 days)

  5. Overall response rate in the overall population

    The proportion of subjects who achieve a confirmed complete response (CR) or partial response (PR) assessed by investigators

    Time frame: During treatment period, an average of 6 months

  6. Disease control rate in the overall population

    The proportion of treated subjects who have achieved complete response, partial response and stable disease

    Time frame: During treatment period, an average of 6 months

  7. Progression-free survival in the overall population

    The time from the entry of the study until progression or death from any cause, whichever occurs first.

    Time frame: 2 years

  8. Overall survival in the overall population

    The time from the entry of the study to the date of death due to any cause or the date of last contact

    Time frame: 5 years

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2023 (actual). Primary completion is estimated for Jun 2026, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2023
First posted
Oct 23, 2023
StartActual
Sep 15, 2023
Primary completionEst.
Jun 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Sep 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06092580
Lead sponsor
Anwita Biosciences
Responsible party
Sponsor
First posted
Oct 23, 2023
Start date
Sep 15, 2023
Primary completion
Jun 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Sep 2, 2025

Study contacts

Eugene Liu, MD, PhD
Contact
contact@anwitabio.com
650-600-9828
Jermaine Coward, BSc (Hons) MBBS MRCP FRACP PhD
principal investigator · Icon Cancer Centre South Brisbane

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha-PD1/IL2 Fusion Protein AWT020

Start the discussion